Retatrutide Trial Records: Adverse Event Evidence Signals FDA
At a glance
- Review question / How do retatrutide studies collect and report evidence about adverse Event Evidence Signals FDA?
- Best evidence / trial protocols, adverse-event tables, and follow-up records
- Evidence snapshot / 2026-08-09
- Commercial status / no FDA-approved product or ordinary retail supply
- HealthRX.com role / independent educational review; no retatrutide product or treatment offer
Evidence map for adverse Event Evidence Signals FDA
| Primary source | What the record documents | What the record cannot establish alone |
|---|---|---|
| Jastreboff et al., phase 2 obesity trial report | Reports a randomized 48-week study in 338 adults and identifies the protocol-defined endpoints and adverse-event collection methods. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| Rosenstock et al., phase 2 type 2 diabetes trial report | Reports a randomized phase 2 study in 281 adults and describes glycemic, body-weight, and adverse-event endpoints. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| Bajaj et al., TRANSCEND-T2D-1 phase 3 report | Reports the design and prespecified endpoints of a completed 40-week phase 3 study in 537 adults with type 2 diabetes. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| ClinicalTrials.gov maintenance-study record NCT06859268 | An active phase 3b record designed to study maintenance and follow-up endpoints through 116 weeks. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
What remains unresolved
Observed events do not establish that retatrutide is safe, safer than another medicine, appropriate for public use, or the cause of every reported event. Rare or delayed outcomes may not be resolved by a trial's size or duration.
What evidence could change the answer
A stronger record would provide complete participant flow, exposure-adjusted event reporting, prespecified definitions, adjudication methods where relevant, and longer follow-up.
Federal regulation distinguishes scientific exchange from promotion: it does not restrict full exchange of scientific information, but it does restrict representing an investigational drug as safe or effective in a promotional context and precludes commercialization before approval.
Source records
Snapshot date: 2026-08-09. Records: Jastreboff et al., phase 2 obesity trial report; Rosenstock et al., phase 2 type 2 diabetes trial report; Bajaj et al., TRANSCEND-T2D-1 phase 3 report; ClinicalTrials.gov maintenance-study record NCT06859268; FDA status statement for unapproved GLP-1 drugs; 21 CFR 312.7, Promotion of investigational drugs.
Frequently asked questions
What is established about adverse Event Evidence Signals FDA?
Public sources document study designs, enrolled populations, prespecified endpoints, and regulatory status. They do not establish an FDA-approved indication, public-use instruction, or conclusion beyond those records.
Does this research mean retatrutide is approved or publicly offered?
No. Retatrutide remains investigational, is not available through ordinary commercial prescription or retail sale, cannot be used in compounding under federal law, and is not offered by HealthRX.com.
How can readers verify this review?
Use the linked FDA, eCFR, PubMed, and ClinicalTrials.gov records. Check the source date, study status, population, endpoint definitions, sponsor, and whether results have been peer reviewed.
References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Phase 2 retatrutide obesity trial report. New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/
- Rosenstock J, Frias J, Jastreboff AM, et al. Phase 2 retatrutide type 2 diabetes trial report. The Lancet. 2023. https://pubmed.ncbi.nlm.nih.gov/37385280/
- Bajaj HS, Welch M, Shah P, et al. TRANSCEND-T2D-1 phase 3 trial report. The Lancet. 2026. https://pubmed.ncbi.nlm.nih.gov/42250575/
- ClinicalTrials.gov. Retatrutide maintenance-study registry record. 2026. https://clinicaltrials.gov/study/NCT06859268
- U.S. Food and Drug Administration. FDA status statement for unapproved GLP-1 drugs. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Electronic Code of Federal Regulations. 21 CFR 312.7, Promotion of investigational drugs. 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.7
